Skip to main content
. 2021 May;10(5):2470–2477. doi: 10.21037/tcr-21-724

Table 3. Two-year prognosis of NSCLC patients with different expressions of Nanog and Fn14.

Index Subgroups Case Dead (n=25), n (%) Survival (n=64), n (%) χ2 P
Nanog expression Positive 61 23 (92.00) 38 (59.38) 8.874 0.003
Negative 28 2 (8.00) 26 (40.63)
Fn14 expression Positive 52 20 (80.00) 32 (50.00) 6.661 0.010
Negative 37 5 (20.00) 32 (50.00)

NSCLC, non-small cell lung cancer.